These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 24850137)

  • 1. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.
    Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH
    World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell vaccines to combat glioblastoma.
    Wheeler CJ
    Expert Rev Neurother; 2010 Apr; 10(4):483-6. PubMed ID: 20367199
    [No Abstract]   [Full Text] [Related]  

  • 5. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of immunotherapy and gene therapy for high-grade gliomas.
    Marsh JC; Goldfarb J; Shafman TD; Diaz AZ
    Cancer Control; 2013 Jan; 20(1):43-8. PubMed ID: 23302906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy trials for glioblastoma multiforme: promise and pitfalls.
    Yong RL; Lonser RR
    World Neurosurg; 2012; 77(5-6):636-8. PubMed ID: 22120230
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
    Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
    Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
    Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
    Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
    Van Gool S; De Vleeschouwer S
    Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccine-based immunotherapy for glioblastoma.
    Thomas AA; Fisher JL; Ernstoff MS; Fadul CE
    CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma.
    Nakano I; Chiocca EA
    World Neurosurg; 2012; 77(5-6):633-5. PubMed ID: 22120228
    [No Abstract]   [Full Text] [Related]  

  • 14. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
    Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S
    J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
    Reardon DA; Mitchell DA
    Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agenus cancer vaccine extends survival of GBM patients.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(2):252-3. PubMed ID: 24963517
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaccine for aggressive brain tumors may prolong survival.
    Health News; 2004 Dec; 10(12):7. PubMed ID: 15645564
    [No Abstract]   [Full Text] [Related]  

  • 19. Trials and tribulations of cancer immunotherapy: the dendritic cell vaccine shows promise in a phase I glioblastoma multiforme trial.
    Gürsel DB; Schlaff CD; Boockvar JA
    Neurosurgery; 2012 Dec; 71(6):N19-21. PubMed ID: 23160396
    [No Abstract]   [Full Text] [Related]  

  • 20. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
    Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
    Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.